Benjamin Lacas
A5015708695- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Head and Neck Surgical Oncology
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Sarcoma Diagnosis and Treatment
- Uterine Myomas and Treatments
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Meta-analysis and systematic reviews
- Brain Metastases and Treatment
- Vascular Tumors and Angiosarcomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Health Systems, Economic Evaluations, Quality of Life
- Breast Implant and Reconstruction
- Hematological disorders and diagnostics
- Statistical Methods in Clinical Trials
- Salivary Gland Tumors Diagnosis and Treatment
- Oral health in cancer treatment
- Neutropenia and Cancer Infections
- Colorectal and Anal Carcinomas
- Cancer survivorship and care
Institut Gustave Roussy
2015-2024
Inserm
2015-2024
Université Paris-Saclay
2016-2023
La Ligue Contre le Cancer
2015-2023
Centre de recherche en Epidémiologie et Santé des Populations
2015-2022
Université Paris-Sud
2015-2021
Cleveland Clinic
2021
Institut Sainte Catherine
2021
Université de Versailles Saint-Quentin-en-Yvelines
2016-2018
Princess Margaret Cancer Centre
2017
Purpose Our previous work evaluated individual prognostic and predictive roles of TP53, KRAS, EGFR in non–small-cell lung cancer (NSCLC). In this analysis, we explore the TP53/KRAS TP53/EGFR comutations randomized trials adjuvant chemotherapy versus observation. Patients Methods Mutation analyses (wild-type [WT] mutant) for were determined blinded fashion multiple laboratories. Primary secondary end points pooled analysis overall survival disease-free survival. We role comutation all...
Chemotherapy, when added to radiotherapy, improves survival in locally advanced nasopharyngeal carcinoma (NPC). This article presents the second update of Meta-Analysis Chemotherapy NPC.Published or unpublished randomized trials assessing radiotherapy (±a chemotherapy timing) with/without non-metastatic NPC patients were identified. Updated data sought for studies included previous rounds meta-analysis. The primary endpoint was overall survival. All analyzed following intent-to-treat...
A standard treatment for fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is yet to be established. In the previous EXTREME trial, few were included. We aimed evaluate efficacy tolerance of an adapted regimen in HNSCC.
Uterine leiomyosarcomas (U-LMSs) and soft tissue (ST-LMSs) are rare tumours with poor prognosis when locally advanced or metastatic, moderate chemosensitivity. In 2015 we reported very encouraging results of the LMS-02 study (NCT02131480) manageable toxicity. Herein, report updated long-term progression-free survival (PFS) overall (OS).Patients received 60 mg/m2 intravenous doxorubicin followed by trabectedin 1.1 as a 3-h infusion on day 1 pegfilgrastim 2, every 3 weeks, up to six cycles....
// Antonin Levy 1,2,3 , Etienne Bardet 4 Benjamin Lacas 5,6 Jean-Pierre Pignon Julien Adam 7 Ludovic Lacroix Xavier Artignan 8,10 Pierre Verrelle 9 and Cécile Le Péchoux 1 Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Institut Thoracique d'Oncologie (IOT), Villejuif, France 2 INSERM U1030, Molecular Radiotherapy, 3 Univ Paris Sud, Kremlin-Bicêtre, Medical de Cancérologie l'Ouest, Nantes, 5 Biostatistics Epidemiology, 6 U1018, CESP, Paris-Sud, Biology Pathology,...
// Angela Boros 1 , Ludovic Lacroix 2 Benjamin Lacas 3, 8, 10 Julien Adam Jean-Pierre Pignon Caroline Caramella 4 David Planchard 5 Vincent de Montpreville 6 Eric Deutsch 1, 7, 9 Antonin Levy Besse 5, 7 Cécile Le Pechoux Radiation Oncology Department, Gustave Roussy, Villejuif, France Biopathology 3 Biostatistics and Epidemiolgy Unit, Imaging Medical Pathology Marie Lannelongue, Plessis Robinson, Paris-Sud University, DHU TORINO, Paris, 8 Paris-Saclay INSERM U1030, U1018,...
10505 Background: U-LMS and ST-LMS are rare tumours with poor prognosis when metastatic or locally advanced, presenting moderate chemosensitivity mainly to doxorubicine (doxo), ifosfamide (ifo), cisplatin, gemcitabine (gem) trabectidine (trab). Response rates (RR) in combination therapies (1 st line) does not exceed 50% for 35% ST-LMS. The most active ones doxo combinations (most of the time ifo dacarbazine) gem + docetaxel (in particular U-LMS) a mean response durations 3 6 months. Trab was...
In stage III non-small cell lung cancer (NSCLC), prophylactic cranial irradiation (PCI) reduces the brain metastases incidence and prolongs progression-free survival without improving overall survival. PCI increases risk of toxicity is currently not adopted in routine care. Our objective was to assess cost-effectiveness compared with no NSCLC from a Dutch societal perspective.A cohort partitioned model developed based on individual patient data three randomized phase trials (N = 670)....